Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07025148 · ClinicalTrials.gov registry record · Phase 4

Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2)

A Phase 4 study of Coronary Arterial Disease (CAD) and Percutaneous Coronary Intervention (PCI), sponsored by University of Florida.

Recruiting
Registry status
Phase 4
Development phase
40
Enrollment target
1
Study location

NCT07025148 is a Phase 4 study of Coronary Arterial Disease (CAD) and Percutaneous Coronary Intervention (PCI) that is actively recruiting participants, run by University of Florida. The registered enrollment target is 40 participants, below the 3,071-participant average among 5 other Coronary Arterial Disease (CAD) trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07025148, a Phase 4 study of Coronary Arterial Disease (CAD) and Percutaneous Coronary Intervention (PCI), is actively recruiting participants, sponsored by University of Florida.

RECRUITING
Registry status
Phase 4
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

The primary aim of this study is to investigate the PD effects of switching from standard-dose clopidogrel dose to low-dose prasugrel versus continuing standard-dose clopidogrel in patients at dual-risk (HBR defined as the HBR-ARC criteria and HIR defined as ABCD-GENE score ≥10) following PCI. We hypothesize that in patients at dual-risk, switching from standard-dose clopidogrel to low-dose prasugrel will be superior to continuing standard-dose clopidogrel in terms of platelet reactivity.

Conditions Studied

Coronary Arterial Disease (CAD) Percutaneous Coronary Intervention (PCI)

Interventions

  • DRUG Clopidogrel
  • DRUG Prasugrel

Study Locations (1)

Florida

  • University of Florida Health - Jacksonville

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2025-10-01
Est. Completion 2027-11-01
Phase Phase 4

Sponsor

University of Florida

1,106 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07025148

The ClinicalTrials.gov registry entry for NCT07025148 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,071-participant average among 5 other Coronary Arterial Disease (CAD) trials with a reported enrollment target (99% lower). The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Coronary Arterial Disease (CAD) appearing as the primary indexed condition, and to 2 interventions - of which Clopidogrel is the first listed.

NCT07025148 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT07025148 about?

NCT07025148 is a clinical study titled "Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2)". The primary aim of this study is to investigate the PD effects of switching from standard-dose clopidogrel dose to low-dose prasugrel versus continuing standard-dose clopidogrel in patients at dual-risk (HBR defined as the HBR-ARC criteria and HIR defined as ABCD-GENE score ≥10) following PCI. We hy...

What is the current status of trial NCT07025148?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2025-10-01. Estimated completion is 2027-11-01.

What conditions does trial NCT07025148 study?

This clinical trial studies the following conditions: Coronary Arterial Disease (CAD), Percutaneous Coronary Intervention (PCI).

What interventions are being tested in trial NCT07025148?

The interventions under investigation include: Clopidogrel (DRUG), Prasugrel (DRUG).

Who is sponsoring clinical trial NCT07025148?

This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07025148 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Coronary Arterial Disease (CAD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Coronary Arterial Disease (CAD)

All registered trials for this condition

Percutaneous Coronary Intervention (PCI)

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.